title: A comparative study on effect of lamivudine in wild and precore mutant variety of chronic hepatitis B virus infected patients.
abstract: The aim of this study is to evaluate the effectiveness of lamivudine treatment in both precore mutant and wild type of chronic hepatitis B (CHB) patients. The study was done on sixty CHB patients of both sexes seeking treatment in the Outpatient Department and admitted patients of Mymensingh Medical College Hospital. The patients were divided into two groups. Group A included chronic hepatitis B patients with raised ALT (> 80 u/l ) with HBeAg positivity, and group B included precore mutant variety of CHB patients with raised ALT (> 80 u/l) with HBeAg negativity. In Group-A, after 1 year of completion of lamivudine therapy there was 86.67% normalization of ALT, 23.33% HBeAg loss, 16.67% anti-HBeAg development and 73.33% HBV DNA loss. In Group-B, there was 76.67% normalization of ALT and 73.33% HBV DNA loss after 1 year of completion of therapy. In the present study, it was observed that lamivudine is equally effective in both wild and precore mutant variety of CHB patients. This was reflected by normalization of ALT and loss of HBV DNA. This study also shows the reappearance of HBV DNA during the later half of Lamivudine therapy which is due to YMDD mutation.
authors.affiliation: Mymensingh Medical College, Mymensingh.
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: M
authors.initials: M
authors.lastname: Khan
authors.forename: C B
authors.initials: CB
authors.lastname: Sarker
authors.forename: C R
authors.initials: CR
authors.lastname: Debnath
authors.forename: Satya Ranjan
authors.initials: SR
authors.lastname: Sutradhar
authors.forename: S R
authors.initials: SR
authors.lastname: Sutradhar
authors.forename: K
authors.initials: K
authors.lastname: Alam
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: N
authors.initials: N
authors.lastname: Ahmed
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D016009:Chi-Square Distribution; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D019259:Lamivudine